How many insider trades does FilingIQ track for KYNB?

FilingIQ tracks 12 Form 4 insider transactions for KYNB (KYNTRA BIO, INC.), covering filings from Feb 3, 2026 onwards. 8 of those were filed in the last 90 days.

Are KYNB insiders net buyers or net sellers?

Across the full Form 4 history for KYNB, 2 transactions (17%) were open-market purchases and 0 (0%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does KYNB insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is KYNB in?

KYNTRA BIO, INC. (KYNB) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $29.77M.

KYNB insider trading

Healthcare

KYNTRA BIO, INC. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

Last 90 days

Buys / sells

17% / 0%

Market cap

$29.77M

About KYNTRA BIO, INC.

Kyntra Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Roxadustat, a small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. Its pipeline products include FG-3165 and FG-3175, an anti-GAL-9 antibody for treatment of solid tumors. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. The company was formerly known as FibroGen, Inc. and change its name to Kyntra Bio, Inc. in January 2026. Kyntra Bio, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.

Company website: www.kyntrabio.com

KYNB insider activity at a glance

FilingIQ has scored 12 insider transactions for KYNB since Feb 3, 2026. The most recent filing in our index is dated Jun 12, 2026.

Across the full history, 2 open-market purchases and 0 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on KYNB insider trades is 66.0/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live KYNB trades on FilingIQ Raw filings on SEC EDGAR

Other Healthcare tickers with recent insider activity

UTHR 1,165

UNITED THERAPEUTICS Corp

APLS 275

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

GH 191

Guardant Health, Inc.

KYMR 178

Kymera Therapeutics, Inc.

First Tracks Biotherapeutics, Inc.

Frequently asked

How many insider trades does FilingIQ track for KYNB?: FilingIQ tracks 12 Form 4 insider transactions for KYNB (KYNTRA BIO, INC.), covering filings from Feb 3, 2026 onwards. 8 of those were filed in the last 90 days.
Are KYNB insiders net buyers or net sellers?: Across the full Form 4 history for KYNB, 2 transactions (17%) were open-market purchases and 0 (0%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does KYNB insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is KYNB in?: KYNTRA BIO, INC. (KYNB) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $29.77M.

Methodology & sources

Every KYNB insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.